Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based.
Socio-Economic Value of Adult Immunisation Programmes
18 April 2024
Adult vaccines can return up to 19 times their initial investment to society, when their significant benefits beyond the healthcare system are monetised.
Around The World in HTAs: Türkiye – The bumpy road toward transformation
31 January 2024
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Prof Hasan Huseyin Yildirim, Dilek Sernur Eminoğulları, Dr Tuba Saygın Avşar, and Patricia Cubi-Molla take us to Türkiye.
Individual, Health System, and Societal Impacts of Anti-seizure Medicine Use During Pregnancy
23 January 2024
Explore the implications of in utero exposure to anti-seizure medications (ASMs), the heightened risks of developmental problems and physical disabilities. The economic impact associated with conditions like epilepsy, stressing the urgent need for detailed risk profiles and data collection to guide interventions and reduce the societal costs linked to ASM use during pregnancy.
Could Plant-based Diets Transform Health Care Spending?
8 January 2024
In a bid to reduce health care budgets, policymakers and healthcare professionals are increasingly looking to prevention strategies.
OHE’s AMR consultation response
21 November 2023
This blog summarises our perspective on the recent proposals set out by NHS England to assess the value of new antibiotics via a new scoring system linked to a volume-delinked revenue guarantee payment. Key arguments outlined here were submitted to NHS England as part of OHE’s response to the consultation on proposals.
Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?
8 November 2023
NHS England conducted a public consultation on a ‘volume-delinked model’ subscription approach to address the market failure hindering the development of urgently needed antibiotics.
Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective
2 November 2023
New antibiotics are urgently needed, but their development is hindered by market failure. A ‘volume-delinked model’ subscription approach has been suggested to overcome this market failure, providing compensation regardless of sales volume.
An eye on sustainability at the Economist’s Future of Health Europe
30 October 2023
Learn more about how the topic of sustainability was tackled by a broad range of speakers and the key themes which emerged.
Around The World in HTAs: Greece – Late but with an Optimistic Future
18 October 2023
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Athanassios Vozikis and Dimitrios Kourouklis take us to Greece.